What is Health2Sync?
Health2Sync operates at the intersection of mobile technology and clinical healthcare, providing a comprehensive platform for patients managing chronic conditions, with a specific focus on diabetes. By integrating user-friendly mobile applications with sophisticated patient management systems, the company facilitates seamless communication between patients and healthcare providers. This ecosystem allows for real-time tracking of health metrics, personalized guidance, and automated reminders, which collectively empower users to achieve better health outcomes. The platform's adherence to ISO standards for information security ensures that sensitive medical data is handled with the highest level of integrity, making it a trusted partner for healthcare systems and insurance providers globally.
How much funding has Health2Sync raised?
Health2Sync has raised a total of $30.5M across 4 funding rounds:
Angel/Seed
$1.5M
Series A
$3M
Series B
$6M
Series C
$20M
Angel/Seed (2014): $1.5M, investors not publicly disclosed
Series A (2016): $3M led by SparkLabs Global Ventures, Cherubic Ventures, iSeed Ventures, and WI Harper Group
Series B (2017): $6M supported by Sompo Holdings, WI Harper, and Alibaba.com
Series C (2025): $20M featuring Abies Capital, Wistron, Pegatron, Cathay Innovation, and Taiwania Capital
Key Investors in Health2Sync
Abies Capital
Abies Capital provides specialized consulting services in finance, strategic planning, and corporate governance to help businesses grow sustainably and securely.
Wistron
Wistron Corporation is a major original design manufacturer and technical services computer company based in Taipei, Taiwan, specializing in contract manufacturing for servers and consumer electronics.
Pegatron
Pegatron Corporation is a leading manufacturer and distributor of information products, consumer electronics, and communication devices headquartered in Taipei.
What's next for Health2Sync?
With the infusion of this latest capital, Health2Sync is well-positioned to scale its digital therapeutics platform into new international markets and deepen its integration with existing healthcare infrastructure. The strategic involvement of industrial partners suggests a focus on hardware-software synergy, potentially expanding the company's reach into broader consumer electronics and connected health devices. As the company moves beyond its current scaling phase, the focus will likely shift toward enhancing its AI-driven predictive analytics to offer even more granular, personalized care plans. By leveraging its extensive network of investors and its proven track record in clinical engagement, Health2Sync is poised to define the next generation of chronic disease management, driving both operational efficiency and improved patient quality of life on a global scale.
See full Health2Sync company page
